Clinical Trial Update: Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating zanubrutinib plus bendamustine-rituximab for newly diagnosed symptomatic Waldenström macroglobulinemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: RECRUITING